MRTX-0902 is under clinical development by Mirati Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRTX-0902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRTX-0902 overview
MRTX-0902 is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer. The drug candidate acts by targeting son of sevenless homolog 1 (SOS1).
Mirati Therapeutics overview
Mirati Therapeutics is a clinical-stage oncology company that carries out the research and development of novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics also offers MRTX1133 – pancreatic cancer and Sitravatinib – Tumor, MRTX1719 -methylthioadenosine phosphorylase (MTAP) deleted cancers and MRTX0902-solid Tumors. The company has partnered with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of MRTX-0902’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - MRTX-0902 in Colorectal Cancer
Premium Insights
The gold standard of business intelligence.
